NDAPERIODONTALFIBER, EXTENDED RELEASE
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ACTISITE (tetracycline hydrochloride) by Pfizer is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. First approved in 1994.
Drug data last refreshed 3h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTISITE is a tetracycline hydrochloride fiber formulation delivered as an extended-release periodontal insert for treating bacterial infections in periodontal disease. It works as a bacteriostatic agent by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, effective against gram-positive, gram-negative, and anaerobic organisms. The drug is administered directly into the periodontal pocket, providing sustained local antibiotic delivery.
LOE Approaching
Product nearing end-of-life with moderate competitive pressure (30%) suggests declining team investment and focus shifting to LOE management and retention strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Microbiology Tetracyclines are primarily…
Indications
Worked on ACTISITE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.